Colon cancer risk and different HRT formulations: A case-control study

BMC Cancer

Volumn 7, Issue , 2007, Pages

  Dinger, Jürgen C ^a   Heinemann, Lothar A J ^a   Möhner, Sabine ^a   Thai, Do Minh ^a   Assmann, Anita ^a  

^a Health Research Berlin   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ESTRADIOL; ESTROGEN; GESTAGEN; MEDROGESTONE; MEDROXYPROGESTERONE ACETATE; TIBOLONE;

ADULT; AGED; ARTICLE; CANCER REGISTRY; CANCER RISK; COLON CANCER; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; HORMONE SUBSTITUTION; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; QUESTIONNAIRE; RISK ASSESSMENT; RISK FACTOR; TREATMENT DURATION; CASE CONTROL STUDY; CHEMISTRY; COLON TUMOR; COMPARATIVE STUDY; MIDDLE AGED;

ADULT; CASE-CONTROL STUDIES; CHEMISTRY, PHARMACEUTICAL; COLONIC NEOPLASMS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MIDDLE AGED; RISK FACTORS;

EID: 34249885869     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-7-76     Document Type: Article

References (13)

1. Writing Group for the Women's Health Initiative Investigators Risks and benefit of estrogen plus progestin in healthy postmenopausal women JAMA 2002 288 321-333 10.1001/jama.288.3.321 12117397
2. Franceschi S La Vecchia C Colorectal cancer and hormone replacement therapy: An unexpected finding Eur J Cancer Prev 1998 7 427-38 10.1097/ 00008469-199812000-00002 9926290
3. Grodstein F Newcomb PA Stampfer MJ Postmenopausal hormone therapy and risk of colorectal cancer: A review and meta-analysis Am J Med 1999 106 574-82 10.1016/S0002-9343(99)00063-7 10335731
4. The Women's Health Initiative Steering Committee Effects of conjugated equine estrogen in postmenopausal women with hysterectomy JAMA 2004 291 1701-1712 10.1001/jama.291.14.1701 15082697
5. Hulley S Furberg C Barrett-Connor E Cauley J Grady D Haskell W Knopp R Lowery M Satterfield S Schrott H Vittinghoff E Hunninghake D HERS Research Group Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II) JAMA 2002 288 58-66 10.1001/jama.288.1.58 12090863
6. Dinger JC Heinemann LAJ Möhner S Do Minh Thai Assmann A Breast cancer risk associated with different HRT formulations: A register-based case-control study BMC Women's Health 2006 6 13 1574290 16965641 10.1186/ 1472-6874-6-13
7. International Agency for Research on Cancer Cancer incidence in five continents (WHO), IARC Scientific Publications No. 155, Lyon Parkin DM, Whelan SLO, Ferlay J, Teppo L, Thomas DB 2002 VIII
8. American Institute for Cancer Research Food, nutrition and the prevention of cancer: A global perspective. Colon (p 216-251) World Cancer Research Fund and American Institute of Cancer Research, Washington (USA) DC 20009 ISBN: 1 899533 05 2
9. Dietel M Lewis MA Shapiro S Hormone replacement therapy: Pathobiological aspects of hormone-sensitive cancers in women relevant to epidemiological studies on HRT: A mini-review Human Reproduction 2005 20 2052-2060 10.1093/humrep/dei043 15932918
10. Issa JP Ottaviano YL Celano P Hamilton SR Davidson NE Baylin SB Methylation of estrogen receptor CpG island links ageing and neoplasia in human colon Nat Genet 1994 7 536-40 10.1038/ng0894-536 7951326
11. Schneider HP HRT and cancer risks: Separating facts from fiction Maturitas 1999 33 S65-S72 10.1016/S0378-5122(99)00065-1 10661617
12. Shapiro S Risk of estrogen plus progestin therapy: A sensitivity analysis of findings in the Women's Health Initiative randomized controlled trial Climacteric 2003 6 302-310 15006251
13. Shapiro S Adverse neoplastic and cardiovascular outcomes of HRT: The validity of the evidence Endocrine 2004 24 203-10 10.1385/ENDO:24:3:203 15542886